Barcelona 2013
Barcelona 2013
Abstract book - Abstract - 264
Go Back

Conference Details
International Committee
Plenary Speakers
Presenting Speakers
Scientific Committee
Abstract #264  -  Co-infection
  8.3: Co-infection (Parallel) on Monday @ 11.00-13.00 in Mirador Chaired by
  Presenting Author:   Mrs Patrizia CARRIERI - INSERM, UMR912, France
  Additional Authors:  Dr Jordi  Casabona, Sra Cristina Sanclemente, Dra Anna Esteve, Dra Victoria Gonzalez, y Grupo HIVITS-TS,  
Addictive behaviors are associated with accelerated liver disease progression and potentially poorer treatment outcomes among patients with hepatitis C virus (HCV) infection. These issues are even more critical among HIV-HCV co-infected patients, who already have lower rates of sustained virological response (SVR) to HCV treatment than their HCV mono-infected counterparts. However, few data exist on the relationships between addictive behaviors and HCV clearance following treatment, especially in the context of HIV-HCV co-infection. We compared addictive behaviors between HIV-infected patients chronically infected with HCV and HIV-infected patients with SVR to HCV treatment.
Method / Issue:
Analyses were based on data collected at enrolment in the French nationwide HEPAVIH (ANRS CO13) cohort of HIV-HCV co-infected patients. Self-reported tobacco, alcohol and street drug use were compared using chi-square and Fisher tests between 101 patients with SVR to HCV treatment (characterized as HCV clearers) and 784 patients with chronic HCV infection who were not currently receiving HCV treatment. Comparisons adjusted for gender and age were then performed using logistic regression models. Sensitivity analyses were conducted to verify the consistency of the results in the subgroup of patients who had already been exposed to HCV treatment.
Results / Comments:
Forty-four percent of HCV clearers reported smoking at least five cigarettes per day (versus 62% of patients with chronic HCV infection, p=0.002), 26% were classified as alcohol abusers according to the AUDIT-C score (versus 35%, p=0.04), 2% reported cocaine use (versus 7%, p=0.05) and 4% reported having used at least one drug (among heroin, cocaine, crack, ecstasy, street buprenorphine, or hallucinogens) during the previous four weeks and/or having injected drugs during the previous six months (versus 9%, p=0.05). Less frequent report of tobacco use among HCV clearers was confirmed in both adjusted models and sensitivity analyses.
Rates of self-reported tobacco, alcohol, and street drug use observed among HIV-HCV co-infected individuals are different between HCV clearers and patients with chronic HCV infection. Further research with a longitudinal design is needed to confirm these differences and to disentangle the potential behavioral and biological underlying mechanisms.
Go Back

  Disclaimer   |   T's & C's   |   Copyright Notice